Genscript Biotech Corporation is a biotechnology company operating through three main platforms. GenScript Life Science Group provides life-science services and products, including gene-to-protein solutions, DNA synthesis, and protein expression for global research communities. ProBio offers end-to-end CRDMO services for biologics development, covering drug discovery through commercialization for modalities such as viral vectors, DNA, RNA, antibodies, and proteins. Bestzyme develops and produces industrial enzymes and functional proteins for applications in biofuel, food and beverage, distilling, starch, household care, textile, and animal feed industries. The company serves customers primarily in North America, Europe, the PRC, and other Asia Pacific regions. It holds an investment in Legend Group and generates license revenue from LaNova.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage genscript.com
Sector Healthcare IR page —
Tags
dna synthesis, crdmo services, industrial enzymes, antibody discovery, protein expression, synthetic biology, biologics development, life science services, GenScript Life Science Group, ProBio, Bestzyme, LaNova, Legend Group
Press page genscript.com/special/press-release

Metrics

Valuation  
Market cap HK$ 68.88B
Market cap (USD) $ 8.778B
P/E -13.79
PEG —
P/BV 2.16
P/S 10.39
P/OCF 62.89
P/FCF —
Dividend yield —
Turnover / mcap 0.88%
Returns  
ROE -12.9%
ROI -12.8%
ROIC -12.8%
Profit margin -55.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 5.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 959.526M 594.486M 839.529M 304.677M 511.062M 390.846M 273.354M 231.017M 152.649M 114.735M 86.709M 69.994M
Net profit -532.83M 2.962B -95.477M -131.202M -347.865M -204.945M -96.912M 21.216M 26.123M 26.17M 17.504M 6.175M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 1.59 1.26 2.45 3.15 4.11 1.52 2.18 2.46 3.21 — — —
Price performance 12m 0.26 -0.49 -0.23 -0.23 1.72 -0.31 -0.12 -0.23 — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

VOLUNTARY ANNOUNCEMENT: UNUSUAL PRICE MOVEMENT Bull 0 Bear 0 Routine

Prompts

Genscript Biotech Corporation (ticker 1548), listed in Hong Kong.

ETFs Holding Genscript Biotech Corporation

ETF Weight in ETF Shares Market value As of
MCH 0.51% 76,000 $ 118.525K Jun 30, 2026
AVEE 0.23% 78,000 $ 297.876K Nov 16, 2026
AVEM 0.10% 6,736,000 $ 25.724M Nov 16, 2026
AVSE 0.10% 54,000 $ 206.222K Nov 16, 2026
DFEM 0.09% 2,014,000 $ 8.174M Nov 12, 2026
AVES 0.05% 195,000 $ 744.69K Nov 16, 2026
DFAE 0.05% 1,076,000 $ 4.367M Nov 12, 2026
DFAX 0.04% 1,162,000 $ 4.716M Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
1548 canonical Common share — HK hkex 30.16 HKD 2026-11-19
2945 delisted Common share — HK hkex 33.90 HKD 2026-11-04